Does Antihypertensive Use Moderate the Effect of Blood Pressure on Cognitive Decline in Older People?


Journal

The journals of gerontology. Series A, Biological sciences and medical sciences
ISSN: 1758-535X
Titre abrégé: J Gerontol A Biol Sci Med Sci
Pays: United States
ID NLM: 9502837

Informations de publication

Date de publication:
30 04 2021
Historique:
received: 03 06 2020
pubmed: 24 11 2020
medline: 17 8 2021
entrez: 23 11 2020
Statut: ppublish

Résumé

While midlife hypertension is deleterious, late-life hypertension has been associated with better cognitive outcomes in several studies. Many questions remain, including the relative benefit or harm of a blood pressure (BP) target and antihypertensive therapy of <120 in very old individuals. The Sydney Memory and Aging Study (n = 1015) comprises a cohort of 70- to 90-year-olds, who were followed biennially for 8 years. Global cognition was assessed with a battery of 10 neuropsychological tests. Blood pressure was measured at Waves 1 and 2 and classified into 3 systolic groupings: group 1 (≤120 mmHg), group 2 (121-140 mmHg), and group 3 (>140 mmHg). Multiple regression, linear mixed modeling, and Cox regression examined the effect of BP and antihypertensives. There were no overall significant differences in global cognition or dementia between the disparate BP groups. However, in those not taking antihypertensives, the systolic BP (SBP) > 140 mmHg group had a significantly worse global cognitive trajectory compared to SBP ≤ 120 mmHg (b = -0.067, 95% CI [-0.129, -0.006], p = .030). Within the SBP ≤ 120 mmHg group those taking antihypertensives had significantly worse global cognition trajectories compared to those not taking antihypertensives even when controlling for past history of hypertension (b = -0.077, 95% CI [-0.147, -0.007], p = .030). Untreated hypertension in old age is related to worse global cognitive decline. However, ongoing treatment at new recommendations of lower SBP targets may be related to poorer cognitive decline and should be considered carefully in older populations.

Sections du résumé

BACKGROUND
While midlife hypertension is deleterious, late-life hypertension has been associated with better cognitive outcomes in several studies. Many questions remain, including the relative benefit or harm of a blood pressure (BP) target and antihypertensive therapy of <120 in very old individuals.
METHODS
The Sydney Memory and Aging Study (n = 1015) comprises a cohort of 70- to 90-year-olds, who were followed biennially for 8 years. Global cognition was assessed with a battery of 10 neuropsychological tests. Blood pressure was measured at Waves 1 and 2 and classified into 3 systolic groupings: group 1 (≤120 mmHg), group 2 (121-140 mmHg), and group 3 (>140 mmHg). Multiple regression, linear mixed modeling, and Cox regression examined the effect of BP and antihypertensives.
RESULTS
There were no overall significant differences in global cognition or dementia between the disparate BP groups. However, in those not taking antihypertensives, the systolic BP (SBP) > 140 mmHg group had a significantly worse global cognitive trajectory compared to SBP ≤ 120 mmHg (b = -0.067, 95% CI [-0.129, -0.006], p = .030). Within the SBP ≤ 120 mmHg group those taking antihypertensives had significantly worse global cognition trajectories compared to those not taking antihypertensives even when controlling for past history of hypertension (b = -0.077, 95% CI [-0.147, -0.007], p = .030).
CONCLUSIONS
Untreated hypertension in old age is related to worse global cognitive decline. However, ongoing treatment at new recommendations of lower SBP targets may be related to poorer cognitive decline and should be considered carefully in older populations.

Identifiants

pubmed: 33225353
pii: 5919549
doi: 10.1093/gerona/glaa232
doi:

Substances chimiques

Antihypertensive Agents 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

859-866

Subventions

Organisme : Medical Research Council
ID : ID350833
Pays : United Kingdom
Organisme : Medical Research Council
ID : ID568969
Pays : United Kingdom
Organisme : Medical Research Council
ID : APP1093083
Pays : United Kingdom

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Matthew J Lennon (MJ)

Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.

Ben Chun Pan Lam (BCP)

Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.

John Crawford (J)

Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.

Henry Brodaty (H)

Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.
Dementia Centre for Research Collaboration, School of Psychiatry, University of New South Wales, Sydney, Australia.

Nicole A Kochan (NA)

Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.

Julian N Trollor (JN)

Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.
Neuropsychiatric Institute, Eastern Suburbs Mental Health Service, Randwick, Australia.

Katya Numbers (K)

Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.

Brian Draper (B)

Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.
Eastern Suburbs Older Persons' Mental Health Service, Randwick, Australia.

Anbupalam Thalamuthu (A)

Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.

Perminder S Sachdev (PS)

Faculty of Medicine, University of New South Wales, Sydney, Australia.
Centre for Healthy Brain Aging (CHeBA), School of Psychiatry, University of New South Wales, Sydney, Australia.
Department of Developmental Disability Neuropsychiatry, School of Psychiatry, University of New South Wales, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH